

Synergistic Therapy for better **Glycemic Management**



In T2DM for Cardio-Renal Protection

^{Rx} Diet, Exercise &

LGpin™-D

Linagliptin 5 mg + Dapagliflozin 10 mg Tablets



In T2DM for Cardio-Renal Protection

Rx Diet, Exercise &

LGpin™-D

Linagliptin 5 mg + Dapagliflozin 10 mg Tablets

Background

- Achieving optimal HbA1c control in patients with Type-2 Diabetes Mellitus often requires more than one therapy. Many standard combinations are limited by side effects or inadequate control. Linagliptin (a DPP-4 inhibitor) and Dapagliflozin (an SGLT-2 inhibitor) offer complementary mechanisms—addressing both insulin secretion and glucose excretion. Clinical evidence shows that their fixed-dose combination not only improves glycemic outcomes but also supports weight reduction and maintains good tolerability, making it a good choice for uncontrolled T2DM.

Product Description:

- **LGpin D** - Linagliptin 5 mg + Dapagliflozin 10 mg tablets

Indications

- **LGpin D** is indicated as an adjunct to diet and exercise **in T2DM for Cardio Renal Protection**

Mechanism of Action

- **Linagliptin:** Inhibits DPP-4 enzyme, prolonging incretin activity (GLP-1, GIP), which increases insulin release and decreases glucagon, leading to reduced hepatic glucose output.
- **Dapagliflozin:** Selectively inhibits SGLT-2 in the kidney, reduces glucose reabsorption and enhances urinary glucose excretion, while contributing to modest weight loss. Together, they deliver improved and sustained glycemic control through complementary pathways.

Dosage

- The recommended dose is one tablet once daily, or as prescribed by the doctor.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019

Tel.: 011-47589500-51 (50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



2025 All rights reserved, Medicamen Lifesciences Pvt Ltd